Sep 08, 2021, 09:00 ET
Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion’s Exclusive Botulinum API Manufacturer
WOBURN, Mass. and JAVENÉ, France, Sept. 8, 2021 /PRNewswire/
Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and other biopolymers, will become Eirion’s exclusive botulinum active pharmaceutical ingredient (API) manufacturer.
Botulinum is the active ingredient in Eirion’s lead product candidate ET-01, a topical neuromodulator being developed for Crow’s Feet wrinkles and primary axillary hyperhidrosis (excessive sweating) that is currently in Phase 2 clinical trials, as well as in their liquid injectable neuromodulator product candidate being developed for glabellar wrinkles,…
Read more…
Like this:
Like Loading...
